OncoMatch/Clinical Trials/NCT05594927
Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)
Is NCT05594927 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Icaritin and Huachansu for hepatocellular carcinoma.
Treatment: Icaritin · Huachansu — A study to evaluate the efficacy and safety of icaritin versus huachansu in the first-line treatment of unresectable hepatocellular carcinoma with poor conditions and biomarker enrichment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy (sorafenib, lenvatinib, donafenib, atezolizumab plus bevacizumab, sintilimab plus a bevacizumab biosimilar, camrelizumab plus apatinib, durvalumab plus tremelimumab, oxaliplatin-based systemic chemotherapy (FOLFOX4), icaritin, huachansu)
No prior first-line systemic treatment for HCC, including sorafenib, lenvatinib, donafenib, atezolizumab plus bevacizumab, sintilimab plus a bevacizumab biosimilar, camrelizumab plus apatinib, and durvalumab plus tremelimumab, oxaliplatin-based systemic chemotherapy (FOLFOX4), icaritin, huachansu, and other anti-cancer drugs such as targeted agents, immune checkpoint inhibitors, and systemic chemotherapy
Lab requirements
Blood counts
platelet ≥ 40×10^9/L, hemoglobin ≥ 80 g/L, white blood cell ≥ 2.0×10^9/L
Kidney function
Serum Creatinine ≤ 1.5x ULN, or creatinine clearance rate ≥ 50 mL/min
Liver function
total bilirubin ≤ 1.5x ULN, ALT and AST ≤ 5x ULN, albumin ≥ 28 g/L, Child-Pugh score ≤ 7
Vital organ functions should meet the following requirements: Hematopoietic function: platelet ≥ 40×10^9/L, hemoglobin ≥ 80 g/L, white blood cell ≥ 2.0×10^9/L; Liver function: total bilirubin ≤ 1.5 times upper limit of normal (ULN), alanine Aminotransferase (ALT) and aspartate Aminotransferase (AST) ≤ 5×ULN; albumin ≥ 28 g/L; Child-Pugh score ≤ 7; Renal function: Serum Creatinine ≤ 1.5×ULN, or creatinine clearance rate ≥ 50 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify